Year: 2024

Based in the Bay Area, Attovia Therapeutics is creating a pipeline of biotherapeutics with an initial focus on immune-mediated diseases. The company leverages Attobody™, a novel biologics platform, to generate small format biparatopic binders that offer stronger efficacy and a broader universe of druggable epitopes compared to traditional approaches. Dr. Hubert Chen, accomplished drug developer…

Allakos, a clinical stage biotechnology company focused on developing novel therapeutics for allergy, inflammatory and proliferative diseases, named Dr. Lee as Chief Medical Officer. Dr. Lee has over 20 years of clinical research and development experience in the biopharmaceutical industry and academia across multiple therapeutic areas, including rheumatology, dermatology, allergy & asthma, and gastroenterology, focused…

Metageno­mi, a pre­ci­sion genet­ic med­i­cines com­pa­ny com­mit­ted to devel­op­ing cura­tive ther­a­peu­tics for patients by lever­ag­ing its metage­nomics-derived genome edit­ing tool­box, named Pamela Wap­nick, MBA, as Chief Finan­cial Officer. Pamela Wap­nick has more than 20 years of diver­si­fied finan­cial lead­er­ship expe­ri­ence span­ning strate­gic and oper­a­tional finance roles. Pri­or to join­ing Metageno­mi, Pamela served as Chief Finan­cial Offi­cer at sev­er­al biotech…

Ambrx Biopharma, a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system, named Renu Vaish, M.Sc., as Chief Regulatory Officer. Ms. Vaish is an experienced leader in U.S. and global regulatory affairs with extensive…

Chartwell Partners proudly announces its collaboration with Neurogene Inc., a pioneering clinical-stage company dedicated to delivering groundbreaking genetic therapies for individuals and families grappling with rare neurological conditions on the recruitment of Julie Jordan, M.D., as their esteemed Chief Medical Officer. With a wealth of experience spanning over two decades in both industry and clinical…

Chartwell Partners is pleased to announce that Dominic Karaba recently joined Veritex Bank as President and Chief Banking Officer, responsible for all customer relationship growth through developing, implementing, and achieving annual goals and objectives. Karaba will be expected to significantly contribute to the strategic planning and direction of the bank by focusing on the core…

Chartwell Partners is pleased to announce that after a thorough search process, Matthew Siekelski was promoted to President and Chief Executive Officer at NexBank. Matt, who previously served as Executive Vice President and Chief Operating Officer of the bank, will be accountable for for increasing shareholder value by consistently enhancing the performance, quality and long-term…

Chartwell Partners is pleased to announce that Brian Johnson recently joined First United Bank as Chief Financial Officer, responsible for leading and establishing the financial strategy that supports the organizations’ return targets within its ongoing strategy. Johnson will collaborate closely with Greg Massey, the CEO, to strategize and shape long-term financial outcomes for the business…

Chartwell Partners is pleased to announce that Stacy M. Brantley recently joined The Citizens Bank as Chief Executive Officer, responsible for all bank operations, strategic direction (in partnership with the Board), people leadership and development, and profitable growth. Brantley will develop and manage the organizational structure, governance framework, and resources required to ensure the effective…

Chartwell Partners is pleased to announce that LaDana Washburn recently joined City Bank’s Board of Directors. Washburn spent her career with EY in the Financial Institutions Group, serving financial services customers for the majority of her career with the exception of a five-year national rotation in the firm’s Risk Practice. On the client side, she…